Patient baseline characteristics
| Placebo | Combined infliximab | Total | |
| Subjects n | 45 | 93 | 138 |
| Age yrs | 45.3±9.4 | 47.8±9.1 | 47.0±9.3 |
| Male | 26 (57.8) | 52 (55.9) | 78 (56.5) |
| Race | |||
| Caucasian | 29 (64.4) | 64 (68.8) | 93 (67.4) |
| Black | 16 (35.6) | 25 (26.9) | 41 (29.7) |
| Asian | 0 (0.0) | 2 (2.2) | 2 (1.4) |
| Other | 0 (0.0) | 2 (2.2) | 2 (1.4) |
| Extrapulmonary involvement | 30 (66.7) | 62 (68.1)# | 92 (67.6) |
| Time since sarcoidosis histologically proven yrs | 7.0±6.2 | 6.9±6.2 | 6.9±6.2¶ |
| FVC L | 2.86±0.77 | 2.82±0.78 | 2.83±0.78 |
| FVC % pred | 68.8±11.1 | 68.6±9.1 | 68.7±9.7 |
Data are presented as mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; % pred: % predicted. #: n = 91; ¶: n = 137.